Why Novartis (NVS) is a Top Value Stock for the Long-Term

Novartis (NVS) is positioned as a top value stock, underpinned by its dominant pharmaceutical portfolio, strategic business reshaping through significant divestitures and acquisitions, and key growth drivers such as Kesimpta and Leqvio. The company holds a Zacks #3 (Hold) rank but features an 'A' VGM Score and a 'B' Value Style Score, supported by an attractive forward P/E of 13.81. Recent analyst activity includes two upward revisions for fiscal 2025 earnings estimates, increasing the consensus to $8.94 per share, making NVS a potential candidate for investors' short lists.

Analysis

Novartis (NVS) maintains a dominant position in the pharmaceutical sector, underpinned by a robust and diversified drug portfolio spanning key therapeutic areas such as cardiovascular, immunology, and oncology across major global markets. The company has strategically reshaped its business through significant divestitures, including the $5.4 billion sale of its Animal Health division in 2015 and the $20.7 billion sale of its Roche investment in 2021, alongside targeted acquisitions like The Medicines Company for Leqvio. This proactive portfolio management aims to optimize its market presence and focus on high-growth areas.

Future growth is anticipated from breakthrough treatments such as Kesimpta, Pluvicto, Scemblix, Kisqali, Leqvio, and Fabhalta, which are expected to fuel revenue expansion. Financially, NVS exhibits attractive valuation metrics, including a forward P/E ratio of 13.81, contributing to its 'B' Value Style Score. The company also boasts an impressive average earnings surprise of +4.6%, indicating consistent outperformance relative to expectations.

Despite holding a Zacks #3 (Hold) Rank, Novartis benefits from a strong 'A' VGM (Value, Growth, Momentum) Score, suggesting a favorable blend of investment characteristics. Analyst sentiment is positive, with two analysts revising fiscal 2025 earnings estimates higher in the last 60 days, pushing the Zacks Consensus Estimate up by $0.10 to $8.94 per share. This upward revision, coupled with its strong Style Scores, positions NVS as a compelling consideration for investors.

Key Decisions for Investors

• Consider NVS for long-term value portfolios given its attractive forward P/E of 13.81, strong 'A' VGM Score, and 'B' Value Style Score.
• Monitor the market penetration and revenue contribution of new growth drivers like Kesimpta and Leqvio, as their success will be crucial for sustained top-line expansion.
• Pay close attention to future analyst estimate revisions for fiscal 2025 and beyond, as continued upward trends would reinforce the positive outlook despite the current Zacks #3 (Hold) Rank.